Previous 10 | Next 10 |
NeoGenomics (NASDAQ:NEO) is scheduled to announce Q4 earnings results on Wednesday, February 24th, before market open.The consensus EPS Estimate is $0.06 (-40.0% Y/Y) and the consensus Revenue Estimate is $123.45M (+15.5% Y/Y).Over the last 2 years, NEO has beaten EPS estimates 88% of the tim...
FT. MYERS, FL / ACCESSWIRE / February 16, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief...
FT. MYERS, FL / ACCESSWIRE / February 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its fourth quarter and full year 2020 financial results on Wednesday, February ...
Access to industry-leading genomic database and real-world evidence designed to optimize trial design, site selection, clinical trial matching and translational research BOSTON, MA, DURHAM, NC and FT. MYERS, FL / ACCESSWIRE / February 4, 2021 / Parexel, a leading provider of solutions t...
NeoGenomics and Tempus Join the Access to Comprehensive Genomic Profiling Coalition PR Newswire WASHINGTON , Feb. 2, 2021 /PRNewswire/ -- The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of NeoGenomics, Inc. (NASDAQ...
Exact Sciences (EXAS), Natera (NTRA), Personalis (PSNL), and Veracyte (VCYT) are all trading sharply higher today, as Truist Securities initiates coverage with buy recommendations on the stocks.With a price target of $65 and ~21.4% of upside to the previous close, the only laggard in the list...
NeoGenomics (NEO) has priced concurrent public offerings of (a) 4,081,632 common shares at $49.00/share for gross proceeds of $200M and (b) $300M aggregate principal amount of its 0.25% convertible senior notes due 2028.Underwriters' over-allotment is an additional 612,244 shares and $45M of ...
NeoGenomics (NEO) commenced proposed underwritten public offerings of ~$200M of newly issued shares and $250M principal amount of convertible senior notes due 2028.Underwriters granted a 30-day option to purchase up to an additional $30M shares and $37.5M notes to cover over-allotments.N...
FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Fin...
NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at consolidating a myriad of oncology diagnostics under one roof via clinical and pharmaceutical ...
News, Short Squeeze, Breakout and More Instantly...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 ...
2024-06-23 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that Fort Myers’ Mayor, Kevin Anderson, will be dedicating June as NeoGenomics’ Commitment to Cancer Month to honor cancer survivors and those currently living with cancer. Headquartered in...